ImCheck Closes Upsized EUR 96 Million (USD 103 Million) Financing to Advance Clinical Program of First-in-human Gamma-delta T Cell Activating Antibody and Accelerate Development of Disruptive Immunotherapeutic Pipeline Significant round will enable the Company to advance ICT01, its lead anti-butyrophilin 3A antibody, to completion of randomized Phase II trialsSeries C adds global investors Earlybird, Andera...

ARMGO Pharma raises $35 million to progress clinical studies of lead molecule ARM210 in cardiac and skeletal muscle diseases ARMGO Pharma raises $35 million to progress clinical studies of lead molecule ARM210 in cardiac and skeletal muscle diseases Series B investment led by Forbion and joined by Pontifax and Kurma...